ArticleFrontiers in pharmacology2022
Editorial: Chemo-Radiation-Resistance in Cancer Therapy.
Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Functional variants in ATF4 and PMAIP1 reveal mitochondrial apoptosis dependencies driving pancreatic cancer progression.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- A Scoping Review of the Challenges and Future Perspectives in the Use of Alpha-Emitters for Metastatic Ovarian Cancer.Molecules (Basel, Switzerland) · 2026Article
- Fish-Derived Antimicrobial Peptides (AMPs) as Anticancer Agents: A Mini-Review ofAnti-cancer agents in medicinal chemistry · 2026Review
- Genomic analysis identifies TJP3 as a prognostic marker for radiotherapy and chemoradiotherapy in oral squamous cell carcinoma.Scientific reports · 2025Article
- Impact of targeting the platelet-activating factor and its receptor in cancer treatment.Military Medical Research · 2025Review
- Radiotherapy resistance driven by Asparagine endopeptidase through ATR pathway modulation in breast cancer.Journal of experimental & clinical cancer research : CR · 2025Article
- The role of Lin28A and Lin28B in cancer beyond Let-7.FEBS letters · 2024Review
- Experimental study of early evaluation of radiosensitivity in mouse models of lung cancers usingEJNMMI research · 2024Article
- Phytocompounds and Nanoformulations for Anticancer Therapy: A Review.Molecules (Basel, Switzerland) · 2024Review
- Optimising of axillary therapy in breast cancer: lessons from the past to plan for a better future.La Radiologia medica · 2024Review
- Acquired Radiation Resistance Induces Thiol-dependent Cisplatin Cross-resistance.Radiation research · 2024Article
- DARS-AS1: A Vital Oncogenic LncRNA Regulator with Potential for Cancer Prognosis and Therapy.International journal of medical sciences · 2024Review
- Article
- Article
- Molecular mechanisms of resveratrol as chemo and radiosensitizer in cancer.Frontiers in pharmacology · 2023Review
- The use of nanomaterials in advancing photodynamic therapy (PDT) for deep-seated tumors and synergy with radiotherapy.Frontiers in bioengineering and biotechnology · 2023Review
- Cancer-Yesterday, Today, Tomorrow.Medicina (Kaunas, Lithuania) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.